New GLP 1 Guidelines for Type 2 Diabetes in 2025 · the ultimate collection

By Olivia

New GLP

New GLP 1 Guidelines for Type 2 Diabetes in 2025
New GLP 1 Guidelines for Type 2 Diabetes in 2025

Updated 2025 GLP-1 guidelines for type 2 diabetes , including clinical insights, prescribing tips, and what healthcare providers need to know.

Unlocking the broad health benefits and risks of GLP 1 receptor agonist
Unlocking the broad health benefits and risks of GLP 1 receptor agonist

The ADA Guidelines 2025 reaffirm metformin as the first-line therapy for Type 2 diabetes unless contraindicated. However, the guidelines give increasing prominence to GLP-1 receptor agonists and SGLT2 inhibitors for patients with cardiovascular or kidney disease, even at early stages of diabetes .

2025 ADA Guidelines

GLP 1 Receptor Agonist Therapies for Weight Loss in India
GLP 1 Receptor Agonist Therapies for Weight Loss in India

The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which - for the first time - includes recommendations for CGM use in type 2 diabetes , the use of GLP-1 drugs for kidney and heart health, and more.

The American Diabetes Association updated the pharmacological glycemic treatment of their "Standards of Care in Diabetes 2025 " to better reflect the use of glucagon-like peptide-1 ( GLP-1 ) medication and treatment of concurrent conditions, such as weight, cardiovascular, and kidney issues. 1

Glucagon like peptide 1 receptor agonists GLP 1 RA dosing dose
Glucagon like peptide 1 receptor agonists GLP 1 RA dosing dose

Summary of Revisions

The field of diabetes care is rapidly changing as new research, technology, and treatments that can improve the health and well-being of people with diabetes continue to emerge. With annual updates since 1989, the American Diabetes Association has long been a leader in producing guidelines that capture the most current state of the field.

The American Diabetes Association (ADA) recently released its 2025 Standards of Care. 1 The updated guidelines bring a fresh focus on diabetes monitoring and treatment, with a stronger call to action to address weight as a key risk factor for the condition. It's important to understand what these changes could mean for your plan members who have or are at risk for diabetes - and what these ...

Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes
Expert Q and A Exploring the Role of GLP 1 Receptor Agonists in Diabetes

Changes to the Standards of Care in Diabetes2025

The American Diabetes Association's (ADA) Standards of Care in Diabetes informs health care professionals about the latest evidence for diagnosing and managing diabetes . The 2025 Standards of Care includes updates to nearly all sections, including revised recommendations for diabetes medications type 1 diabetes testing evidence-based eating patterns The updated Standards of Care also ...

Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes.

Patient education tips for GLP 1 weight loss drug treatment
Patient education tips for GLP 1 weight loss drug treatment

Stay Current on Med Recommendations for Diabetes

You'll continue to see SGLT2 inhibitors and GLP-1 agonists gain traction as first-line agents for many adults with type 2 diabetes ... Learn more with Pharmacist's Letter.

Weight Loss Drugs GLP 1 Agonists Brown and Brown
Weight Loss Drugs GLP 1 Agonists Brown and Brown
GLP 1 Receptor Agonist Medications Sugar Detox Lab
GLP 1 Receptor Agonist Medications Sugar Detox Lab
GLP 1 Medications for T1D What your endo wants you to know Diabetes
GLP 1 Medications for T1D What your endo wants you to know Diabetes
Comparing Ozempic Wegovy and Other GLP 1 Drugs GoodRx
Comparing Ozempic Wegovy and Other GLP 1 Drugs GoodRx
GLP 1 Receptor Agonist Medications Sugar Detox Lab
GLP 1 Receptor Agonist Medications Sugar Detox Lab
Alimentary Pharmacology and Therapeutics Pharmacology Journal
Alimentary Pharmacology and Therapeutics Pharmacology Journal
Unlocking the broad health benefits and risks of GLP 1 receptor agonist
Unlocking the broad health benefits and risks of GLP 1 receptor agonist

The standards for diabetes management from the American Diabetes Association (ADA) have evolved significantly in recent years, and their 2025 standards recommend SGLT2 inhibitors and GLP1 RAs as first-line, glucose-lowering medications for all patients with diabetes . 2 Moreover, the recommendation highlights the use of GLP1 RAs for the primary ...